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Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, and 36-
69% of PTC cases are caused by mutations in the BRAF gene. The substitution of a valine 
for a glutamic acid (V600E) comprises up to 95-100% of BRAF mutations; therefore, most 
diagnostic methods, including allele-specific PCR and real-time PCR, are designed to de-
tect this mutation. Nevertheless, other mutations can also comprise the genetic back-
ground of PTC. Recently, a novel and sensitive technique called mutant enrichment with 
3’-modified oligonucleotides (MEMO) PCR has been introduced. When we applied allele-
specific PCR and MEMO-PCR for the detection of the BRAF V600E mutation, we found an 
unusual 3’ bp deletion mutation (c.1799_1801delTGA) only when using MEMO-PCR. This 
deletion results in the introduction of a glutamic acid into the B-Raf activation segment 
(p.V600_K601delinsE), leading to an elevated basal kinase activity of BRAF. This is the 
first report of a rare 3 bp BRAF deletion in a PTC patient that could not be detected by al-
lele-specific PCR.
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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common malig-
nant thyroid tumor. In the past, RET/PTC oncogene activation 
was considered the genetic hallmark of PTC, despite the rela-
tively low prevalence (5-30%) of RET/PTC oncogene activation 
in adult PTC patients [1]. However, after Davies et al. [2] re-
ported that the BRAF gene is frequently mutated in a variety of 
human tumors, many studies have reported a particularly high 
prevalence of BRAF mutations in PTC (36-69%) [1, 3, 4].
  The BRAF gene encodes a cytoplasmic serine/threonine ki-
nase that is a member of the Raf family of kinases located down-
stream of Ras in the Ras/Raf/extracellular signal-regulated ki-
nase (ERK) cell signaling pathway. Constitutive activation of the 
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Ras-Raf kinase-signaling pathway promotes uncontrolled cell 
division, resulting in carcinogenesis [4]. A single substitution, 
valine to glutamic acid at codon 600 (V600E), accounts for 95%-
100% of all BRAF mutations in thyroid carcinoma [1, 4, 5]. Only 
a few other BRAF mutations have been documented, such as 
the substitution of a lysine with a glutamate at codon 601 (K601E) 
in patients with follicular variant of PTC [5]. Therefore, most di-
agnostic methods, including allele-specific PCR (AS-PCR) and 
real-time PCR, are designed to detect the BRAF V600E mutation. 
  Recently, a novel and sensitive technique called mutant en-
richment with 3’-modified oligonucleotides (MEMO) PCR has 
been introduced [6]. The method is based on the use of a 3’- 
modified oligonucleotide primer that blocks extension of the nor-
mal allele but enables extension of the mutated alleles. In this 
study, we describe an unusual 3 bp deletion mutation (c.1799_ 
1801delTGA) in a thyroid nodule that was identified only by us-
ing the MEMO-PCR and sequencing method. 
CASE REPORT
A 47-yr-old woman visited our hospital for further evaluation of 
multiple thyroid masses. These masses were detected based on 
abnormal results of thyroid ultrasonography at a local hospital. 
The largest mass was isoechoic, measured approximately 2×2.8 
cm, and had the appearance of a benign nodule. However, a 
smaller 0.5-cm-sized nodule located in the lower pole of left thy-
roid was hypoechoic and had a spiculated appearance, and 
was suspected to be malignant. The patient underwent thyroid 
function tests, including triiodothyronine (T3), thyroxine (T4), 
and thyroid-stimulating hormone (TSH) tests. Fine-needle aspi-
ration biopsy and BRAF mutational analysis were performed on 
the suspicious lesion. 
  A thyroid aspiration sample was collected from the patient af-
ter obtaining informed consent. Genomic DNA was isolated from 
the sample using the QIAamp DNA Mini Kit (Qiagen, Chatsworth, 
CA, USA) according to the manufacturer’s instructions. AS-PCR 
was performed to detect V600E substitutions in the BRAF gene 
using the Seeplex V600E ACE detection kit (Seegene, Seoul, Ko-
rea). Although AS-PCR of a positive control for the BRAF V600E 
mutation produced PCR products at 538 and 335 bp as ex-
pected, only the 538 bp band, characteristic of the wild-type se-
quence, was amplified from our patient (Fig. 1). MEMO-PCR 
was then performed. The ability of this method to detect trace 
mutant alleles is superior to that of conventional methods [6]. In 
MEMO-PCR, 2 generic primers and a blocking primer were used 
to amplify BRAF exon 15. The 3’-end of the blocking primer was 
modified by the addition of a C3 spacer, a phosphate, or a C6 
amine; these 3’ modifications inhibit the amplification of normal 
alleles. Five microliters of the amplification product was treated 
with 2 U shrimp alkaline phosphatase and 10 U exonuclease I 
(USB Corp., Cleveland, OH, USA). Direct sequencing was per-
formed using the BigDye Terminator Cycle Sequencing Ready 
Reaction Kit on an ABI Prism 3130 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA). The obtained sequences 
were analyzed using the Sequencher program (Gene Codes 
Corp., Ann Arbor, MI, USA) and were compared to a reference 
sequence (GenBank accession number NM_004333.4). 
  Thyroid function tests of the patient indicated that the levels 
of the following test items were all within normal limits: T3, 95.6 
ng/dL (reference interval (RI), 76-190 ng/dL); T4, 1.02 ng/dL (RI, 
0.64-1.72 ng/dL); and TSH, 1.25 μIU/mL (RI 0.3-6.5 μIU/mL). 
According to the MEMO-PCR analysis, the BRAF mutation in 
our case was a 3 bp deletion in coding nucleotides 1799 to 1801 
(c.1799_1801delTGA), which fall within the BRAF mutational 
BRAF V600E
BRAF (816 bp)
600V (538 bp)
600E (335 bp)
positive control
Patient
Fig. 1. Allele-specific PCR results. At left, two PCR products at 538 
and 335 bp were amplified for the positive control of BRAF V600E; 
at right, the patient with the BRAF deletion mutation only showed a 
wild-type band at 538 bp.
Fig. 2. Direct sequencing of exon 15 of the BRAF gene after MEMO- 
PCR. Top, wild-type BRAF; bottom, a 3 bp deletion of coding nucle-
otides 1799 to 1801 (c.1799_1801delTGA; arrow).
Abbreviation: MEMO-PCR, mutant enrichment with 3’-modified oligonucle-
otides-PCR.
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hotspot region in which the V600E and K601E mutations are 
found (Fig. 2). The result of the deletion mutation is the conver-
sion of codons 600 (GTG) and 601 (AAA) into a single codon 
(GAA), resulting in the introduction of glutamic acid into the 
BRAF activation segment (p.V600_K601delinsE), mimicking the 
BRAF V600E and K601E mutations. To confirm this result, we 
performed conventional PCR and sequencing of the BRAF gene; 
heterozygous peaks were observed from a starting position at 
nucleotide 1799 (Fig. 3). 
  Later, the patient underwent left lobectomy for a lesion that 
was suspected of being a thyroid carcinoma. The histological 
study of the nodule revealed classical papillary microcarcinoma. 
The cut surface of the confirmed lesion showed a whitish, round, 
and firm nodule measuring 0.5×0.5 cm. Metastatic deposits 
were detected in 1 out of 7 resected lymph nodes. 
DISCUSSION
In the present study, we identified of a rare 3 bp BRAF gene de-
letion in a thyroid nodule by using a MEMO-PCR and sequencing 
method. This unusual deletion mutation could not be detected 
by AS-PCR. Until now, the 3 bp deletion (c.1799_1801delTGA) 
that was detected in this study has previously been reported in 
only 3 cases: a melanoma, a serrated adenoma, and a solid 
variant of papillary carcinoma [7-9]. The rarity of BRAF deletion 
mutations suggests that this mutation may have less tumori-
genic potential than the BRAF V600E and K601E mutations [9]. 
Another hypothesis is that a deletion mutation has less chance 
of occurring than a single-nucleotide substitution. Finally, the 
possibility of underestimating the incidence of these deletion 
mutations because of “mutation-specific” screenings, such as 
mutant-allele-specific PCR, should not be overlooked. Currently, 
many laboratories perform AS-PCR and real-time PCR for de-
tection of BRAF V600E, which is the most prevalent mutation in 
PTC. However, initial restriction of screening to the hotspot re-
gion of BRAF mutations in thyroid tumors, specifically a thymi-
dine to adenine substitution at nucleotide position 1799, may 
obscure detection of a deletion or other mutations in exon 15 of 
the BRAF gene, as described in our current case. 
  Recently, the ability to identify minority mutant DNAs has be-
come essential for characterizing the early and post-treatment 
tumor status in cancer patients. Mutant-enrichment processes 
that increase the amount of mutant allele relative to the wild-
type allele have therefore attracted great interest [10]. There are 
many moderate- to high-selectivity PCR methods for mutant en-
richment, such as amplification refractory mutation system 
PCR, thermostable restriction endonuclease-mediated selective 
PCR, and PCR clamping mediated by peptide nucleic acid (PNA) 
or locked nucleic acid (LNA) [10]. These techniques are attrac-
tive, but the time and cost required for optimization may ham-
per their widespread use. MEMO-PCR is a novel mutant enrich-
ment technique that is simpler and more practical method than 
prior enrichment PCR methods. This technique is based on the 
use of a 3’-modified oligonucleotide primer for blocking exten-
sion of the normal allele, which is much less expensive and is 
easy to design compared with PNA or LNA. In MEMO-PCR, 2 
generic primers (which amplify both mutant and wild-type al-
leles) and a blocking primer constitute the PCR reaction mix-
ture. The 3’-modified blocking primer is designed to be modified 
with an extension-inhibiting compound, to encompass the tar-
get BRAF V600E site, and is complementary to the wild-type se-
quence. If there is a BRAF V600E mutation present in the pa-
tient, the affinity of the primer for the mutant allele is less than 
that for the wild-type allele, due to nucleotide mismatches. As a 
result, mutant alleles will be selectively amplified. It has been 
documented that the MEMO-PCR and sequencing method can 
enrich for minority alleles that are present in wild-type DNA at 
concentrations as low as 10
-2 to 10
-6 depending on the concen-
trations and thermodynamics of the primers [6]. The enrich-
ment efficiency of MEMO-PCR is comparable to that of PNA-
mediated PCR clamping when reaction conditions are optimized 
[6]. This accurate and cost-effective technique may be practi-
cally applicable in clinical and diagnostic settings. In the current 
study, MEMO-PCR with sequencing was capable of detecting a 
rare BRAF deletion mutation successfully. The 3 bp deletion se-
quence was easily distinguished from that of the wild-type se-
quence (Fig. 2). 
  In 2005, V. Trovisco et al. reported a new BRAF triplet deletion 
for the first time in a case of PTC [9]. A 47-yr-old woman under-
went a total thyroidectomy after the clinical diagnosis of a multi-
nodular goiter. The tumor had the characteristics of PTC, dis-
playing a predominantly solid growth pattern [9]. A BRAF muta-
Fig. 3. Confirmation of the deletion mutation using conventional 
PCR and sequencing. Top, wild-type BRAF; bottom, heterozygous 
peaks were observed from a starting position at nucleotide 1799 
(arrow).
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tion was identified using PCR with single-strand conformation 
polymorphism analysis, and a 3 bp deletion was detected in the 
tumor tissue (c.1799_1801delTGA). Our case provides another 
example of a BRAF deletion mutation in PTC. The histological 
type of the current case is the classical type of PTC, not the solid 
variant. Given the rarity of BRAF deletions, it is not possible to 
determine whether the mutation is associated with a specific 
histological type of PTC. Further studies using a large series of 
cases are needed to clarify this point. 
  In conclusion, we identified a rare 3 bp deletion of the coding 
nucleotides 1799 to 1801 of BRAF in a PTC patient using MEMO- 
PCR and sequencing. The MEMO-PCR and sequencing method 
may be a useful tool for successful identification of a rare dele-
tion mutation of the BRAF gene as well as the detection for clini-
cally significant low-level mutant alleles.
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